Recursion Pharmaceuticals

Recursion is one of the most advanced AI-driven drug discovery companies, combining high-throughput biological experimentation (phenomics) with advanced AI models and the BioHive-2 supercomputer to map and navigate human biology at scale. Following its 2024 merger with Exscientia ($688M), Recursion operates an end-to-end platform spanning from target identification through clinical development. The combined entity has more than 10 clinical and preclinical programs, partnerships with Roche/Genentech and Bayer, and approximately $600M in cash as of end of 2024.

$600M+ cash position (end of 2024)

Total raised

End-to-end drug discovery platform combining high-throughput phenomics (cellular imaging at massive scale), the Phenom-2 foundation model, generative chemistry (from Exscientia), and the BioHive-2 NVIDIA DGX SuperPOD supercomputer. The Recursion OS maps trillions of biological and chemical relationships to identify therapeutic starting points.